InvestorsObserver
Sign Up Login

ASLN Aslan Pharmaceuticals Ltd ADR

$1.50 $0.00 (0.00%)
Add to Watchlist Compare
Overall

ASLN Stock Analysis Overview

What this means: InvestorsObserver gives Aslan Pharmaceuticals Ltd ADR (ASLN) an overall rank of 39, which is below average. Aslan Pharmaceuticals Ltd ADR is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 39 means that 61% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

View Sample Report
Fundamental PREMIUM

ASLN Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

Short-Term Technical PREMIUM

ASLN Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

Long-Term Technical PREMIUM

ASLN Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

Analyst Ranking PREMIUM

ASLN Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

Valuation PREMIUM

ASLN Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

Stock Sentiment PREMIUM

ASLN Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

ASLN Stock Analysis Overview

What this means: InvestorsObserver gives Aslan Pharmaceuticals Ltd ADR (ASLN) an overall rank of 39, which is below average. Aslan Pharmaceuticals Ltd ADR is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock's chart. A rank of 39 means that 61% of stocks appear more favorable to our system.

Who this matters to: Overall Ranking is a comprehensive evaluation. It considers technical and fundamental factors and is a good starting point for evaluating a stock.

Create a FREE account to see full ASLN report

ASLN Fundamental Analysis

Who this matters to: The Fundamental Ranking considers the health of the underlying company. It is best used by longer-term buy-and-hold investors.

Upgrade to Premium to unlock Fundamental Ranking

ASLN Short-Term Technical Analysis

Who this matters to: The Short-Term Technical Ranking evaluates a stock’s trading over the past month. This is most useful for short- to medium-term stock and option traders.

Upgrade to Premium to unlock Short-Term Technical Ranking

ASLN Long-Term Technical Analysis

Who this matters to: The Long-Term Technical Ranking is a good gauge of how a stock has traded over the past several months. This is useful for medium to long-term stock and option traders.

Upgrade to Premium to unlock Long-Term Technical Ranking

ASLN Analyst Ranking

Who this matters to: Analyst Ranking shows you which stocks Wall Street analysts like the most. Since analysts build valuation models, this is most useful for medium to long-term investors who are interested in a valuation-based approach.

Upgrade to Premium to unlock Analyst Ranking Analysis

ASLN Valuation Ranking Analysis

Who this matters to: Valuation Ranking is most-useful for value-focused investors who plan to hold a stock for the long term.

Upgrade to Premium to unlock Valuation Ranking

ASLN Stock Sentiment Analysis

Who this matters to: Sentiment Rank looks at the past five trading days. This is our shortest-term evaluation and is best used by people with a very short horizon.

Upgrade to Premium to unlock Stock Sentiment Ranking

Aslan Pharmaceuticals Ltd ADR (ASLN) Analyst Forecast

ASLN Price, Volume, Earnings, and Dividend Date

  • Last Price $1.50
  • Previous Close $1.50
  • Change $0.00
  • Open $1.39
  • Volume 535,100
  • Avg. Volume (100-day) 847,452
  • Market Cap 104,425,818
  • Days Range 1.38 - 1.57
  • 52-week Range 1.13 - 6.75
  • Dividend Yield —
  • Ex. Dividend Date —
  • P-E —
  • EPS —
  • Earnings Date 01/24/22
  • Sector Healthcare
  • Industry Biotechnology
  • Avg. Analyst Rec. Premium
  • Beta 2.285
  • PEG Ratio —

Aslan Pharmaceuticals Ltd ADR (ASLN) Company Description

ASLAN Pharmaceuticals Ltd is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.

Aslan Pharmaceuticals Ltd ADR (ASLN) Stock Chart

View Interactive ASLN chart

My Watchlists

Follow Your Favorite Stocks

Top Stocks in Biotechnology

Company Price
Crinetics Pharmaceuticals Inc (CRNX) (CRNX) $26.35
Fireman B.V. (IFRX) (IFRX) $4.56
Bellus Health Inc (BLU) (BLU) $5.89
Adicet Bio Inc (ACET) (ACET) $14.49
Atyr Pharma Inc (LIFE) (LIFE) $8.19
Eyepoint Pharmaceuticals Inc (EYPT) (EYPT) $14.75
Tricida Inc (TCDA) (TCDA) $7.86
Cytokinetics (CYTK) (CYTK) $37.47
Opiant Pharmaceuticals Inc (OPNT) (OPNT) $29.94
Regeneron Pharmaceuticals (REGN) (REGN) $635.09